Affordable Access

deepdyve-link
Publisher Website

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.

Authors
  • Urbi, Berzenn1, 2
  • Broadley, Simon1, 2
  • Bedlack, Richard3
  • Russo, Ethan4
  • Sabet, Arman5, 2
  • 1 Neurology, Gold Coast Hospital and Health Service, Southport, Queensland, Australia. , (Australia)
  • 2 School of Medicine, Griffith University, Gold Coast, Queensland, Australia. , (Australia)
  • 3 School of Medicine, Duke University, Durham, North Carolina, USA.
  • 4 International Cannabis and Cannabinoids Institute, Prague, Czech Republic. , (Czechia)
  • 5 Neurology, Gold Coast Hospital and Health Service, Southport, Queensland, Australia [email protected] , (Australia)
Type
Published Article
Journal
BMJ Open
Publisher
BMJ
Publication Date
Nov 11, 2019
Volume
9
Issue
11
Identifiers
DOI: 10.1136/bmjopen-2019-029449
PMID: 31719072
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3-5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy of cannabinoids in extending the survival and slowing of disease progression in animal models with ALS. There are anecdotal reports of cannabis slowing disease progression in persons with ALS (pALS) and that cannabis alleviated the symptoms of spasticity and pain. However, a clinical trial in pALS with these objectives has not been conducted. The Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease trial is a randomised, double-blind, placebo-controlled cannabis trial in pALS conducted at the Gold Coast University Hospital, Australia. The investigational product will be a cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration. A total of 30 pALS with probable or definite ALS diagnosis based on the El Escorial criteria, with a symptom duration of <2 years, age between 25 and 75years and with at least 70% forced vital capacity (FVC) will be treated for 6 months. The primary objective of the study is to evaluate the efficacy of CBME compared with placebo in slowing the disease progression measured by differences in mean ALS Functional Rating Scale-Revised and FVC score between the groups at the end of treatment. The secondary objectives are to evaluate the safety and tolerability of CBME by summarising adverse events, the effects of CBME on spasticity, pain, weight loss and quality of life assessed by the differences in mean Numeric Rating Scale for spasticity and Numeric Rating Scale for pain, percentage of total weight loss and ALS specific quality of life-Revised questionnaire. The study has been approved by the local Institutional Review Board. The results of this study will be published in a peer-reviewed journal. NCT03690791. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Report this publication

Statistics

Seen <100 times